Yale Cancer Center gives guidance for cancer patients who want COVID boosters
While most people who contracted the COVID-19 virus are back to enjoying their normal activities surrounded by others, that’s not the case for those who have undergone cancer or leukemia treatments and have weakened immune systems. Yale Cancer Center researcher Jeffrey Townsend decided to make that dilemma his recent focus. He extrapolated data from many studies already done on COVID-19. Townsend said the Centers for Disease Control Preventions’ guidelines for immunocompromised patients is to get boosters “as needed.” Wanting to know more, Townsend set out with another researcher to give patients some guidance based on science.Source: WTNH News 8
Engaging People with Low-Grade Glioma in Cancer Research
Some people with low-grade glioma, a type of brain tumor, can live for years, even decades, without the disease worsening. But eventually these cancers start to grow, and little is known about why—or how—this happens. An NCI-supported study called OPTIMUMExit Disclaimer (Optimizing Engagement in Discovery of Molecular Evolution of Low-Grade Glioma) could provide some answers.Source: National Cancer Institute
Research reveals boosting strategies that mitigate risks of COVID-19 in cancer patients
New research led by scientists at Yale University and the University of North Carolina at Charlotte finds that the rate at which additional COVID-19 boosters are needed for cancer patients depends on the treatment they are receiving.
Prominent Statistician Opens Dean’s Speaker Series
Big data has transformed the landscape of modern public health research. But there are limits to its applications and researchers need to pay more attention to potential biases. That was the key message delivered by prominent statistician Professor Bhramar Mukherjee, who presented the inaugural lecture for the Yale School of Public Health's new “Leaders in Public Health" speaker series.
When should I get another COVID booster?
Even as Covid-19 recedes from its position as America’s third-leading cause of death in 2022, it remains on track to be a top-ten cause of death this year with the emergence of new variants, such as XBB.1.5 (representing 84 percent of U.S. cases as of April 1). Given the latest federal guidelines on boosters, the public understandably seeks clarity about what this all means for them. Here’s what you need to know about getting your next vaccine.Source: Smithsonian Magazine
Fan Li Receives New PCORI Award to Develop Causal Inference Methods for Stepped-Wedge Cluster Randomized Trials
Dr. Fan Li, an assistant professor of biostatistics at the Yale School of Public Health, has received approval of a 3-year funding award from the Patient-Centered Outcomes Research Institute (PCORI) to develop causal inference methods for stepped-wedge cluster randomized trials—a design that has been increasingly adopted in pragmatic trials.Source: NIH Pragmatic Trials Collaboratory Website
YSPH biostatistician part of award-winning Yale team
Staff Spotlight on Jesse Reynolds, a biostatistician at the Yale Center for Analytical Sciences (YCAS) who oversees Yale University's ClinicalTrials.gov team. He's also part of REDCap data collection team that was recently presented the Lorimer Award for Distinguished Service by the university.
Multidisciplinary COPPER Center Brings a Public Health Lens to Cancer Care
Studying cancer treatment outcomes is the mission of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, a collaborative effort of the Yale Cancer Center and the Schools of Medicine and Public Health.Source: Yale Public Health magazine
Annual or Biannual Boosters Are Optimal for Fighting Endemic COVID-19, Study Shows
A team of scientists led by faculty at the Yale School of Public Health and the University of North Carolina at Charlotte finds that updated boosters administered on an annual or biannual basis greatly reduce the long-term risk of infection from endemic COVID-19.